Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-03-28 Annual Report
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2023' which translates to 'Annual Report 2023'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and management details, industry information, corporate governance, and financial accounting reports. The document includes audited financial data, management's discussion and analysis, and comprehensive company information for the fiscal year 2023. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-28 Chinese
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various proposals including the 2023 annual supervisory board work report, the 2023 annual report and its summary, the 2023 financial settlement report, the 2024 financial budget report, profit distribution, reappointment of the accounting firm, use of idle raised funds, and internal control self-evaluation report. The document repeatedly states that these reports have been or will be submitted to the shareholders' meeting for approval and are published on the Beijing Stock Exchange website with announcement numbers. The document itself is a meeting resolution announcement, not the actual annual report or financial report. The length is about 3,041 characters, which is relatively short and consistent with a meeting resolution announcement. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board meeting resolutions and approvals, not the full annual report or financial statements themselves.
2024-03-28 Chinese
天健会计师事务所（特殊普通合伙）关于江苏德源药业股份有限公司募集资金年度存放与使用情况鉴证报告
Regulatory Filings
2024-03-28 Chinese
2023年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 Annual Performance Express Announcement" and contains preliminary financial data for the year 2023, including revenue, net profit, earnings per share, and asset information. It explicitly states that the data is preliminary and unaudited, with final audited figures to be disclosed in the formal 2023 Annual Report. The document is relatively short (2120 characters) and serves as a performance preview or earnings summary rather than a full annual report. It does not contain full financial statements or detailed analysis typical of a 10-K or full Annual Report. This type of document aligns with an Earnings Release (ER), which provides initial key financial highlights for a fiscal year before the full report is published. FY 2023
2024-02-25 Chinese
关于原一致行动人协议到期终止、部分股东重新签署一致行动人协议暨实际控制人变更的公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement regarding the expiration and termination of a previous "一致行动人协议" (acting-in-concert agreement), the signing of a new such agreement by some shareholders, and the resulting change in the actual controlling shareholders of the company. It includes detailed shareholder information, shareholding percentages, and explanations about the stability of control and governance. The document is not a financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement. It is a regulatory announcement about changes in shareholder agreements and actual control of the company, which affects the company's control structure but does not report financial results or management changes per se. This fits best under the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels and control. The document length (7357 characters) and content confirm it is a full announcement, not a brief notice or a report publication announcement. Therefore, the classification is MRQ with high confidence.
2024-02-06 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司实际控制人变更的法律意见书
Regulatory Filings
2024-02-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.